Dr. Sacks originally came to Mount Sinai to work with Thomas C. Chalmers, a pioneer in what is now called "evidence-based medicine." His work has been in two categories: 1) the design, conduct and analysis of clinical and natural history studies (primary studies), to provide new data to directly answer clinical questions, and 2) synthesis of existing data by meta-analysis, decision analysis and cost-effectiveness analysis, to provide guidance for urgent clinical problems for which primary data are not (or not yet) available. Dr. Sacks' current research interests include clinical trials, infections in the elderly, HIV, complementary and alternative therapies.
Dr. Sacks is also Director for Clinical Research of Mount Sinai's Complementary and Alternative Medicine (CAM) Center, and co-director of Mount Sinai's Fogarty International AIDS Training program.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sacks during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Pfizer Pharmaceuticals
Editorial Services
American College Of Physicians
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sacks during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Pfizer Pharmaceuticals
Editorial Services
American College Of Physicians
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
